Stock CALTX CALLIDITAS THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Company Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Pharmaceuticals

Real-time Estimate Cboe Europe
Other stock markets
 04:15:45 2024-04-25 am EDT 		5-day change 1st Jan Change
102.2 SEK +1.74% Intraday chart for Calliditas Therapeutics AB +0.10% -19.67%
Apr. 24 Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings MT
Apr. 24 Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results CI

Business Summary

Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

Number of employees: 181

Sales per Business

SEK in Million2021Weight2022Weight Delta
Out-licensing of the Product Candidate
52.5 %
225 98.2 % 422 52.5 % +87.21%
Therapeutics for Renal Disease Immunoglobulin
46.8 %
- - 376 46.8 % -
Performance of Certain Regulatory Services
0.4 %
4 1.8 % 3 0.4 % -17.29%
Royalty
0.3 %
- - 2 0.3 % -

Sales per region

SEK in Million2021Weight2022Weight Delta
United States
46.4 %
-- 372 46.4 % -
Asia
35.7 %
27 12.0 % 287 35.7 % +943.64%
Europe
17.9 %
202 88.0 % 144 17.9 % -28.69%

Managers

Managers TitleAgeSince
Renée Aguiar-Lucander CEO
 Chief Executive Officer 62 17-05-17
Fredrik Johansson DFI
 Director of Finance/CFO 47 17-07-31
Richard Philipson CTO
 Chief Tech/Sci/R&D Officer 60 20-07-23
Krassimir Mitchev CTO
 Chief Tech/Sci/R&D Officer - 19-02-28
Johan Erik Häggblad CTO
 Chief Tech/Sci/R&D Officer 65 07-03-31
Åsa Hillsten IRC
 Investor Relations Contact - 23-03-31
Monika Tornsen PRN
 Corporate Officer/Principal 45 Jan. 06
Christopher Ngai PRN
 Corporate Officer/Principal - 20-03-31
Frank Bringstrup LAW
 General Counsel 65 19-01-31
Sandra Frithiof HRO
 Human Resources Officer 49 22-07-10

Members of the board

Members of the board TitleAgeSince
Fred Driscoll BRD
 Director/Board Member 73 23-05-29
Henrik Stenqvist BRD
 Director/Board Member 57 21-12-31
Elmar Schnee CHM
 Chairman 65 19-05-07
Hilde Furberg BRD
 Director/Board Member 65 14-08-31
Margareta Elisabeth Björk BRD
 Director/Board Member 62 21-12-31
Diane Parks BRD
 Director/Board Member 71 19-05-07

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 59,580,087 43,663,885 ( 73.29 %) 5,908,018 ( 9.916 %) 73.29 %

Shareholders

NameEquities%Valuation
LINC AB
10.01 %
5,963,966 10.01 % 63 M kr
CALLIDITAS THERAPEUTICS AB
9.916 %
5,908,018 9.916 % 63 M kr
BVF Partners LP
9.692 %
5,774,433 9.692 % 61 M kr
Industrifonden
5.280 %
3,145,828 5.280 % 33 M kr
Fjärde AP-fonden
4.470 %
2,663,000 4.470 % 28 M kr
Unionen (Investment Management)
3.310 %
1,972,100 3.310 % 21 M kr
Sofinnova Partners SAS
2.360 %
1,406,090 2.360 % 15 M kr
E. Öhman J :or Fonder AB
2.230 %
1,328,635 2.230 % 14 M kr
LSP Advisory BV
1.420 %
845,886 1.420 % 9 M kr
Renée Aguiar-Lucander
1.079 %
643,000 1.079 % 7 M kr
NameEquities%Valuation
BVF, Inc.
2.518 %
750,000 2.518 % 16 M kr
DWS Investment GmbH
0.1697 %
50,550 0.1697 % 1 M kr
Ironwood Investment Management LLC
0.0854 %
25,435 0.0854 % 534 389 kr
Susquehanna Securities LLC
0.0316 %
9,412 0.0316 % 197 746 kr
Wells Fargo Clearing Services LLC
0.005035 %
1,500 0.005035 % 31 515 kr
Vision2020 Wealth Management Corp.
0.003934 %
1,172 0.003934 % 24 624 kr
Optiver Holding BV
0.003290 %
980 0.003290 % 20 590 kr
UBS Securities LLC
0.003196 %
952 0.003196 % 20 002 kr
Planning Capital Management Corp.
0.002944 %
877 0.002944 % 18 426 kr
Citadel Securities GP LLC
0.002776 %
827 0.002776 % 17 375 kr

Holdings

NameEquities%Valuation
CALLIDITAS THERAPEUTICS AB
9.92%
 5,908,018 9.92% 62,657,308 $

Company contact information

Calliditas Therapeutics AB

D5, Kungsbron 1

111 22, Stockholm

+46 84 11 30 05

http://www.pharmalink.se
address Calliditas Therapeutics AB(CALTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Specialty & Advanced Pharmaceuticals

Sales per Business

Sales per region

Ratings for Calliditas Therapeutics AB

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
100.4 SEK
Average target price
208 SEK
Spread / Average Target
+107.17%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
CALLIDITAS THERAPEUTICS AB Stock Calliditas Therapeutics AB
-19.67% 495M
MERCK KGAA Stock Merck KGaA
+4.34% 70.78B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.72% 9.15B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-15.34% 4.84B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+34.54% 4.22B
YUHAN CORPORATION Stock Yuhan Corporation
+5.09% 3.92B
INDIVIOR PLC Stock Indivior PLC
+18.57% 2.55B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-28.33% 2.24B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-24.15% 2.26B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+6.23% 1.92B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CALTX Stock
  4. Company Calliditas Therapeutics AB